We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3 the central protein in the... Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3 the central protein in the complement cascade. Show more
WALTHAM Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals,Β Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company...
WALTHAM, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals,Β Inc., (Nasdaq: APLS) today announced that the company will participate in the following December investor conferences:...
WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals,Β Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Jefferies London Healthcare...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.2299 | -3.68785607196 | 33.35 | 33.83 | 32.1201 | 921863 | 33.0156895 | CS |
4 | -1.8099 | -5.33421750663 | 33.93 | 35.72 | 31.76 | 2654829 | 33.79572196 | CS |
12 | 4.8501 | 17.7854785479 | 27.27 | 35.72 | 24.34 | 3266742 | 29.82389867 | CS |
26 | -6.3699 | -16.5494933749 | 38.49 | 42.47 | 24.34 | 2468203 | 31.80713206 | CS |
52 | -27.7699 | -46.3681749875 | 59.89 | 73.8 | 24.34 | 1992302 | 40.41731224 | CS |
156 | -13.6899 | -29.884086444 | 45.81 | 94.75 | 19.8301 | 1965069 | 47.52842542 | CS |
260 | 3.4301 | 11.9557337051 | 28.69 | 94.75 | 16.85 | 1579122 | 45.78036216 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions